MJR will participate in the n-TRACK project Open Day Workshop, which will take place at Trinity Hall, in Cambridge, UK on the 30th October 2019. You are welcome to participate in this workshop related to use of nanomaterials in biomedical applications. Participation to workshop is free but registration is required. You can find the registration form at nTRACK website ( ) Download the registration form and send it back filled to This email address is being protected from spambots. You need JavaScript enabled to view it.. This would be a great opportunity to learn about the progress of the project, meet the project partners and learn about technologies they are developing related to nanomaterials in biomedical applications. We are also using this opportunity to invite guests and speakers that are not directly involved in the project, but interested in commercialisation of technologies being develop. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 761031. This publication reflects only the author’s views and the European Union is not liable for any use that may be made of the information contained therein.

MJR PharmJet is part of  European Space Agency Topical Team, Tissue Healing in Space.  Market forecasts are extremely positive for all the domains covered directly and indirectly ( i.e. through networking) by the participant to the Topical Team. For example, the regenerative medicine market is expected to grow up to 68 billion USD by 2020 with a promising growth rate of 23% per year. Also, the medical sensors market is reported from different sources to reach about 10 billion USD in 2020 with a growth rate of 30% per year. Many segments of those markets could directly take advantage of the research topics presented in this proposal and of their study and development in the space environment. Experiments in Space will help at a better understanding of the repair mechanisms of wounded tissues, the development of more effective wound dressing and enhanced wound and suture healing as well as improve knowledge on tissue regeneration possibly by using stem cells, platelets, growth factors, drugs and physical therapies. It is straightforward to understand the potential impact that one of this research topics could have on the global healthcare market.

For more information: ESA Topical Team webpage

CPhI Worldwide, organized by UBM, announced the winners of the prestigious 2017 CPhI Pharma Awards during a live gala dinner at the Intercontinental Hotel in Frankfurt this week. The Awards celebrate and recognise pharmaceutical excellence, and strongly encourage companies that are committed to participate in the growing and evolving pharma industry. MJR PharmJet triumphed in the ‘Manufacturing Technology and Equipment’ category with the MicroJet Reactor technology



For more information:

6,8€ Million Granted to nTRACK Horizon 2020 Project Designed to Study Multimodal Nanoparticles for Muscle Regeneration

Grant from European Union’s Horizon 2020 programme to nTRACK project designed to study multimodal nanoparticles for structural and functional tracking of stem cell therapy on muscle regeneration

The European Union has awarded a grant of 6,8 million Euro to nTRACK collaborative project. The grant, from the Horizon 2020 framework programme, was awarded to nTRACK, a research and innovation project carried out by an international consortium led by LEITAT. The project partners are: MJR PharmJet, Bar Ilan University, Pluristem Therapeutics, University of Mainz, BET Solutions, National Centre for Scientific Research “Demokritos”, Vall d'Hebron Research Institute, Vivotecnia Research, RIVM, Asphalion, and Cambridge Nanomaterials Technology. The project will officially be launched on the 16th of October in Barcelona.

Press release nTrack Horizon 2020 Project

MJR PharmJet has been shortlisted as finalist in the category 4. Manufacturing Technology and Equipment" in the CPhI Pharma Awards 2017!






For more information:

The European Commission grants “npSCOPE” project bringing together nine partners including MJR PharmJet to develop a new integrated instrument for accurate and reproducible physicochemical characterisation of nanoparticles as part of the “H2020-NMBP: CALL FOR NANOTECHNOLOGIES, ADVANCED MATERIALS, BIOTECHNOLOGY AND PRODUCTION” program. The npSCOPE project aims at developing a new integrated instrument (the nanoparticle-scope) optimised for providing a complete physico-chemical characterisation of nanoparticles both in their pristine form or embedded in complex matrices such as biological tissues. Using sophisticated correlative data processing methodologies and algorithms based on statistical methods in conjunction with appropriate visualisation methods of the results, the npSCOPE instrument will allow rapid, accurate and reproducible measurements.

For more information:

MJR PharmJet participates in the European research project “N2B-Patch” project financed by the European Commision for the call “H2020-NMBP: CALL FOR NANOTECHNOLOGIES, ADVANCED MATERIALS, BIOTECHNOLOGY AND PRODUCTION” program. The N2B-Patch project brings Universities, Research institutes, SMEs and Industry with complementary distinct expertise out of chemical, biological, regulatory and business areas. Project aims to  develop a new innovative nose to brain drug delivery technology based on the synthesis of a biomaterial-based innovative galenic formulation that will be applied with the aid of a novel medical device equipped with a container closure system as a hydrogel patch to the nasal olfactory region for the chronic treatment of MS. 

For more information: N2B-Patch webpage



MJR PharmJet`s  Soapbox application has been accepted for presentation at the 2015 CRS Annual Meeting & Exposition held in Edinburgh, Scotland. Soapbox sessions of the Annual CRS Meetings are well-attended, highly interactive part of the program giving an opportunity companies to present new ideas, products and services. CRS official website reports that Soapbox sessions attract attendees from “Big Pharma, biotechs, product formulators, licensing officers, venture capitalists, technology transfer offices, universities—in essence, anyone and everyone who has an interest in exploring the hottest innovations and tools”. MJR PharmJet was selected among a huge number of applicants with proposed presentation titled “ Microjet Reactor Technology for Continuous Nanoparticle Production under Controlled Conditions”. 

CPhI Worldwide, organised by UBM Live, announced the winners of the 11th annual CPhI live Pharma Awards. The annual awards showcase outstanding developments and innovations from the pharma industry's most dynamic and progressive players. Open to the entire pharma industry, the awards honour companies that are driving the industry forward with thought leadership, unveiling top pharma innovators to global trade. In addition to returning annual award categories for 'Formulation', 'Process Development' and 'Packaging', a new category recognising 'Innovation in Partnering' debuts this year. Supported by Pharmaceutical Outsourcing magazine, this award honours partnering methods, use of technology, unexpected outcomes and unique partnering practices.

The awards panel deliberated for several hours over the impressive list of entries, before coming to the unanimous decision, selecting MJR PharmJet in the Formulation category:

By forming counter-ion complexes, the solubility of the API can be improved without chemically altering it, allowing nanoparticles with an enhanced load to be formed via the company's microjet technology. The principle has been proved via a formulation of the drug ciprofloxacin for cystic fibrosis patients, creating a nanodelivery system that allows the drug to penetrate the thick mucus that forms in their lungs. The employed technology can be applied to a wide range of molecules and different markets, including nutraceuticals and cosmetics. 

The 2015 Gips-Schüle Research Award in the amount of EUR 50,000 goes to the research project “Nanoparticles for the Environmentally Compatible Production of Organic Solar Cells” of Karlsruhe Institute of Technology (KIT) in cooperation with MJR PharmJet GmbH. The project in which engineers, physicists, chemists, and biologists cooperate is aimed at developing low-cost methods for the production of new solar cells without any solvents that are harmful to human health.

“Photovoltaics is a major component of electricity supply based on renewable sources. Current growth rates suggest that its relevance will significantly increase in the future. Hence, it is very important to use “green” technologies for production already,” the President of KIT, Professor Holger Hanselka, says. “The novel process developed by KIT in cooperation with industry is not only highly innovative, but also sustainable and inexpensive. The Gips-Schüle Research Award is a wonderful recognition of this great achievement.”